📋 Pharmacy/Drug Stores (PHA)

Federal lobbying activity for the pharmacy/drug stores issue area

🤖

AI Overview

Pharmacy/Drug Stores (PHA) has attracted $262.2M in lobbying spending across 9,053 filings. This issue area sees targeted lobbying from organizations with specific policy interests.

$262.2M

Total Spending

9,053

Total Filings

$417.1M

Estimated Spending

Spending by Year

Top Clients

#	Client	Spending
1	Pharmaceutical Research and Manufacturers of America	$8.2M
2	Walgreen Co.	$7.1M
3	Cvs Health	$5.0M
4	Endo USA, INC., a Mallinckrodt-endo Company	$4.2M
5	PHRMA	$3.4M
6	Viatris INC	$3.3M
7	Cigna Corporation	$3.1M
8	Consumer Healthcare Products Association	$3.1M
9	Genentech, INC.	$2.9M
10	Pharmaceutical Care Management Association (Pcma)	$2.9M
11	Healthcare Distribution Alliance (Healthcare Distribution Managment Assn.)	$2.9M
12	Unitedhealth Group, INC.	$2.9M
13	Community Oncology Alliance	$2.8M
14	Healthcare Distribution Alliance	$2.8M
15	Eli Lilly and Company	$2.7M
16	National Association of Chain Drug Stores	$2.6M
17	The Campaign for Sustainable Rx Pricing	$2.6M
18	Neurocrine Biosciences, INC.	$2.6M
19	America's Health Insurance Plans	$2.5M
20	Travere Therapeutics	$2.5M

Top Lobbying Firms

#	Firm	Revenue
1	Mehlman Consulting, INC.	$14.6M
2	Todd Strategy Group	$11.6M
3	Rubicon Advisors, LLC	$9.0M
4	Kountoupes Denham Carr & Reid, LLC	$8.9M
5	BGR Government Affairs	$8.8M
6	Marshall & Popp, LLC	$7.4M
7	Tarplin, Downs & Young, LLC	$6.9M
8	Foley & Lardner LLP	$6.8M
9	Brownstein Hyatt Farber Schreck, LLP	$5.8M
10	Forbes-tate	$5.7M
11	Farragut Partners LLP	$4.9M
12	Akin Gump Strauss Hauer & Feld	$4.2M
13	Invariant LLC	$3.6M
14	Ricchetti Incorporated	$3.6M
15	Penn Avenue Partners	$3.5M
16	Red+blue Strategies	$3.3M
17	The Kpm Group DC LLC	$3.3M
18	Ballard Partners	$3.3M
19	Acg Advocacy	$3.0M
20	Fierce Government Relations	$2.6M

Sample Lobbying Descriptions

•Drug shortages and FDA approval. USTR acceptance.

•drug pricing, drug supply chain, opioid abuse epidemic, Medicare Part D

•Controlled Substance act improvements. Opioid overdose death reduction. Alprazolam rescheduling.

•Federal government relations service, strategy development and implementation relating to companys status of FDA action on NDA for oral testosterone.

•Issues related to health insurance and prescription drug pricing.

•Time-Temperature Indicators for Pharmaceuticals; and Drug Quality and Security Act

•Issues relating to the regulations around drug manufacturing.

•Drug FDA Approval: CAM2038

•Federal government relations service, strategy development and implementation relating to status of FDAs action with regards to the companys NDA.

•Federal government relations service, strategy development and implementation relating to regenerative medicine products.